Synaptotagmin-12, a synaptic vesicle phosphoprotein that modulates spontaneous neurotransmitter release

Anton Maximov,1 Ok-Ho Shin,1 Xinran Liu,1 and Thomas C. Südhof1,2,3

1Center for Basic Neuroscience, 2Department of Molecular Genetics, and 3Howard Hughes Medical Institute, UT Southwestern Medical Center, Dallas, TX 75390

Central synapses exhibit selective spontaneous neurotransmitter release that is selectively regulated by cAMP-dependent protein kinase A (PKA). We now show that synaptic vesicles contain synaptotagmin-12, a synaptotagmin isoform that differs from classical synaptotagmins in that it does not bind Ca2+. In synaptic vesicles, synaptotagmin-12 forms a complex with synaptotagmin-1 that prevents synaptotagmin-1 from interacting with SNARE complexes. We demonstrate that synaptotagmin-12 is phosphorylated by cAMP-dependent PKA on serine97, and show that expression of synaptotagmin-12 in neurons increases spontaneous neurotransmitter release by approximately threefold, but has no effect on evoked release. Replacing serine97 by alanine abolishes synaptotagmin-12 phosphorylation and blocks its effect on spontaneous release. Our data suggest that spontaneous synaptic-vesicle exocytosis is selectively modulated by a Ca2+-independent synaptotagmin isoform, synaptotagmin-12, which is controlled by cAMP-dependent phosphorylation.

Introduction

Presynaptic terminals release neurotransmitters in two modes: evoked release, which is induced by Ca2+ flowing into the nerve terminal when stimulated by an action potential, and spontaneous release, which occurs in the absence of massive Ca2+ influx (Katz, 1969). Evoked release is clearly the more important form of release in terms of how the brain processes information, but many observations indicate that spontaneous release may also be physiologically important, and not just an “accident” of turbocharged presynaptic release machinery (for reviews see Otsu and Murphy, 2003; Zucker, 2005). This evidence suggests that “spontaneous” synaptic-vesicle exocytosis causing miniature postsynaptic currents (minis) may be mechanistically distinct from evoked exocytosis and independently regulated, and that minis may have a biological function.

Mechanistically, minis appear to derive from a vesicle pool that differs from that which feeds evoked release (Sara et al., 2005). Although evoked and spontaneous release both require SNARE proteins, deletions of the vesicular SNARE protein synaptobrevin/VAMP2 differentially alter evoked and spontaneous release (Deitcher et al., 1998; Schoch et al., 2001), and structure/function studies suggest that the sequences of synaptobrevin required for evoked and spontaneous release differ (Deak et al., 2006). Moreover, spontaneous and evoked release appear to be differentially regulated by Ca2+ (Llano et al., 2000; Angleson and Betz, 2001).

Physiologically, minis may have a substantial function in regulating neural networks. In cultured hippocampal slices, blocking all release by botulinum toxin had a dramatic effect on spine morphology, whereas blocking only evoked release by tetrodotoxin did not (McKinney et al., 1999). Similarly, in cultured hippocampal neurons, spontaneous release was shown to stabilize synaptic function through tonic suppression of dendritic protein synthesis (Sutton et al., 2006). In addition, in small cerebellar interneurons, a single excitatory or inhibitory quantum, which is what is released by a mini event, can trigger or inhibit, respectively, the generation of an action potential (Carter and Regehr, 2002).

In synapses of mouse cortical and hippocampal neurons, and in Drosophila melanogaster neuromuscular junctions, evoked synchronous neurotransmitter release is triggered by Ca2+ binding to synaptotagmin-1 (Geppert et al., 1994; Fernández-Chacón et al., 2001; Yoshihara and Littleton, 2002; Nishiki and Augustine, 2004; Maximov and Südhof, 2005), whereas synaptotagmin-2 performs a similar role in brainstem synapses (Pang et al., 2006). In addition to mediating synchronous Ca2+-triggered release, synaptotagmin-1 and -2 both normally restrict spontaneous release (Pang et al., 2006), suggesting that they are
intrinsic components of the release machinery. We now find that another member of the synaptotagmin family, synaptotagmin-12, is colocalized with synaptotagmin-1 on synaptic vesicles, but is expressed much later in development. Synaptotagmin-12 was originally described as a thyroid hormone–inducible protein (Thompson, 1996) that is homologous to synaptotagmin-1, but lacks its Ca\(^{2+}\)-binding sequences, suggesting that it does not participate in Ca\(^{2+}\) triggering of release. We demonstrate that expression of synaptotagmin-12 in cultured neurons at a time when no endogenous synaptotagmin-12 can be detected causes a dramatic and selective increase in spontaneous release. Moreover, we show that synaptotagmin-12 is phosphorylated by cAMP-dependent protein kinase A (PKA) at a single site, and that mutation of this site blocks the effect of synaptotagmin-12 on spontaneous release, suggesting that this phosphorylation activates its up-regulation of spontaneous release. Finally, we demonstrate that synaptotagmin-12 forms a tight constitutive complex with synaptotagmin-1 on synaptic vesicles, but regulates spontaneous release independently from synaptotagmin-1. Our data suggest a function for a Ca\(^{2+}\)-independent synaptotagmin isoform in modulating spontaneous release.

**Results**

**Expression of synaptotagmin-12**

We generated an antibody against the linker sequence between the transmembrane region and C\(_2\) domains of synaptotagmin-12. As expected from the lack of sequence homology between synaptotagmin isoforms in the linker region, the synaptotagmin-12 antibody recognized only this isoform, but no other synaptotagmin (Fig. 1 A). Immunoblotting revealed that synaptotagmin-12 is expressed in the brain and adrenal medulla. (C) Expression of synaptotagmin-12 could not be detected in cultured cell lines. (D) Analysis of indicated rat tissues isolated at different stages of development ranging from embryonic day 18 to postnatal day 40 (as shown on the right side of each image), shows that expression of synaptotagmin-12 is restricted to postnatal brain and displays progressive increase during development. (E and F) Relative expression levels of synaptotagmin-1 and -12 were determined by quantitative immunoblotting of total brain homogenates isolated from mouse at different stages of postnatal development and cortical neurons isolated from newborn mouse pups and cultured in vitro for 5–15 d. (E) Raw immunoblotting data. (F) Quantification of expression with \(^{125}\)I-labeled secondary antibodies. The relative expression levels of each protein were plotted as the percentage of expression in adult brains \((n \geq 4)\). Similar results were obtained with cultured hippocampal neurons (not depicted). Data are shown as the mean ± the SEM.

**Localization of synaptotagmin-12 to synaptic vesicles**

Immunoblotting of tissue homogenates isolated from various regions of adult brain (Fig. 2 A) and immunolabeling of brain sections (Fig. 2 B) revealed that synaptotagmin-12 is abundantly expressed throughout the brain, with the highest expression...
levels in cerebellum. This labeling was specific because preincubation with the antigen greatly reduced synaptotagmin-12 immunoreactivity in brain sections (Fig. 2 C). To establish the localization of native synaptotagmin-12, we fractionated the brain homogenates and analyzed the distribution of synaptotagmin-12 in different subcellular fractions. Synaptotagmin-12 was highly enriched in the fraction that contains synaptic vesicles (Fig. 2 D).

Because subcellular fractionation is imprecise, we next tested the localization of synaptotagmin-12 by measuring its
levels in the brains of synapsin 1/2 double knockout mice. In these brains, synaptic vesicles are selectively decreased in numbers, and thus the levels of all synaptic vesicle proteins are decreased, whereas the levels of other proteins, e.g., active zone proteins, plasma membrane proteins, or cytosolic proteins, are unchanged (Rosahl et al., 1995). Indeed, we found that synaptotagmin-12 was reduced by ~40% in the synapsin-deficient brains, which exactly corresponds to the decrease observed for other synaptic vesicle proteins (Fig. 2, E and F). The levels of synaptic proteins that are not localized on synaptic vesicles, such as the synaptotagmin isoforms 3, 6, and 7 or NMDA-receptors, were not decreased in synapsin double knockout mice (Fig. 2, E and F).

To obtain a higher resolution localization, we cultured cortical neurons from newborn mice or rats. We first attempted to localize endogenous synaptotagmin-12 in the cultured neurons, but surprisingly, could not detect any synaptotagmin-12 in the neurons even after prolonged culture (Fig. 1 E). Quantitations of the levels of synaptotagmin-1 and -12 revealed that whereas the concentration of synaptotagmin-1 continuously increased in the neurons as a function of culture time, synaptotagmin-12 remained at levels below the sensitivity of our assay, even after 15 d in vitro (DIV; Fig. 1 E). Thus, interestingly, synaptotagmin-12 is present in cultured neurons below the levels observed in the brains from which the neurons were obtained, suggesting that additional factors in brain that are absent under culture conditions must contribute to the regulation of synaptotagmin-12 expression.

To be able to localize synaptotagmin-12 in cultured neurons by immunofluorescence labeling, we therefore expressed recombinant synaptotagmin-12 with a lentivirus. We found that recombinant synaptotagmin-12 was targeted to synapses where it precisely colocalized with synaptophysin (Fig. 2, I and J). Synaptic vesicle localization of native synaptotagmin-12 was supported by immunohistochemical analysis of brain sections from adult mice that showed that synaptotagmin-12 is distributed in a typically synaptic pattern (Fig. S1, available at http://www.jcb.org/cgi/content/full/jcb.200607021/DC1), and by immunoelectron microscopy that revealed synaptotagmin-12 immunoreactivity over the vesicle cluster in presynaptic terminals (Fig. 2, G and H). Together, these data show that synaptotagmin-12 is a synaptic vesicle protein.

Biochemical properties of synaptotagmin-12

Vesicular targeting of synaptotagmin-1 is regulated by N-glycosylation (Han et al., 2004). To determine whether synaptotagmin-12 is also glycosylated, we tested the effects of various deglycosylating enzymes on the mobility of native synaptotagmin-12 during SDS-PAGE. In agreement with a previously published report (Han et al., 2004), removal of neuraminic acid and O- and N-linked sugars with sialidase, O-glycanase, PNGase, or different combinations of these enzymes resulted in a dramatic change in the mobility of synaptotagmin-1, but had no effect on the mobility of synaptotagmin-12, suggesting that synaptotagmin-12 is not glycosylated (Fig. 3 A).

To test whether synaptotagmin-12 interacts with phospholipids, we performed phospholipid-binding assays with the recombinant C2AB domain of synaptotagmin-12, using the C2AB domain of synaptotagmin-1 as a positive control. Consistent with the primary sequence analysis that indicated that synaptotagmin-12 lacks Ca\textsuperscript{2+}-binding sequences, no Ca\textsuperscript{2+}-dependent phospholipid binding was observed when the C2AB domain of synaptotagmin-12 was tested alone or in the presence of C2AB domains of synaptotagmin-1 (Fig. 3 B).

PKA-dependent phosphorylation of synaptotagmin-12

A screen of the phosphorylation of different synaptotagmins in synaptosomes that were incubated with $^{32}$Porthophosphate revealed that the strongest labeling with $^{32}$P under the conditions used was obtained for synaptotagmin-12 (Fig. 4 B and not depicted). To identify which protein kinase may mediate synaptotagmin-12 phosphorylation, we immunoprecipitated synaptotagmin-12 from nonlabeled brain extracts and incubated the immunoprecipitated synaptotagmin-12 with brain lysate in the presence of 1 mM ATP and 10 μCi γ-$^{32}$P]ATP alone or with addition of 0.1 mM cAMP, 0.1 mM cGMP, or 1 mM Ca\textsuperscript{2+}. Without additions, no synaptotagmin-12 phosphorylation was detected, but cAMP caused strong phosphorylation (Fig. 4 C).
cGMP induced marginal phosphorylation, possibly because cGMP at the high dose used (0.1 mM) can stimulate PKA, whereas Ca\(^{2+}\) did not stimulate any synaptotagmin-12 phosphorylation (Fig. 4 C).

We searched the synaptotagmin-12 sequence for potential PKA phosphorylation sites and identified two such sites in the synaptotagmin-12 linker region (T87 and S97; Fig. 4 A). To determine whether one or both of these are being used, we first tested whether recombinant fragments of synaptotagmin-12, produced as GST-fusion proteins, were phosphorylated by PKA. Only the linker region, but not the C\(_2\) domains, were phosphorylated (Fig. 4 D). We next tested whether mutation of either T87 or S97 alters phosphorylation of the linker by PKA. We found that phosphorylation was completely abolished by substituting serine\(^{97}\) with alanine, whereas substituting threonine\(^{97}\) with alanine had no effect (Fig. 4 E), suggesting that synaptotagmin-12 is phosphorylated by PKA on serine\(^{97}\). To determine whether the PKA phosphorylation site in synaptotagmin-12 is evolutionarily conserved, we compared the linker sequences from different species. Although no significant homology was found between fly and vertebrate synaptotagmin-12 linker sequences (unpublished data), serine\(^{97}\) with a canonical preceding lysine residue was found to be conserved in all vertebrate synaptotagmin-12 homologues from zebrafish to humans (Fig. 4 F).

**Figure 4.** Synaptotagmin-12 is phosphorylated in a cAMP-dependent manner at serine\(^{97}\). (A) Schematic diagram of synaptotagmin-12 domain structure. A fragment of linker sequence containing two putative sites for PKA-dependent phosphorylation (T87 and S97, marked by asterisks) is illustrated below. (B) In vivo phosphorylation of native synaptotagmin-12. The proteins from rat brain synaptosomes preincubated with [\(^{32}\)P]orthophosphate were extracted in detergent and immunoprecipitated with antibody to synaptotagmin-12 or preimmune serum. Incorporation of [\(^{32}\)P] was measured with x-ray film. Note that a single ~50 kD band is observed in synaptotagmin-12, but not in control immunoprecipitation. (C) In vitro phosphorylation of native synaptotagmin-12. Proteins extracted from brain were immunoprecipitated with synaptotagmin-12 antibody or preimmune serum attached to Sepharose beads. The beads were incubated with brain cytosol mixed with 1 mM ATP and 10 \(\mu\)Ci \([\(^{32}\)P]ATP\) alone or with addition of 0.1 mM cAMP, 0.1 mM cGMP, or 1 mM Ca\(^{2+}\). Note that synaptotagmin-12 is strongly phosphorylated in a cAMP-dependent manner. (D and E) Identification of a functional PKA phosphorylation site in synaptotagmin-12 sequence. (D) Indicated fragments of synaptotagmin-12 were expressed as recombinant GST fusion proteins [top shows Coomassie staining of all fusion proteins; the asterisk corresponds to GST] and phosphorylated in vitro in the presence of catalytic subunit of PKA and \([\(^{32}\)P]ATP. Note that only linker region of synaptotagmin-12 is phosphorylated. (E) Phosphorylation of wild-type synaptotagmin-12 linker GST fusion protein and linkers containing single alanine substitutions in residues T87, S97, or a combination of these mutations. Note that phosphorylation is completely abolished in S97A mutant. The asterisk corresponds to GST. (F) Multiple sequence alignment of synaptotagmin-12 homologues from different species shows the fragments of the linker sequences containing conserved PKA phosphorylation site (marked by black boxes).
whereas noninfected neurons and neurons expressing mutant synaptotagmin-12 exhibited no significant $^{32}$P labeling (Fig. 5 A, bottom). These data suggest that under the conditions used, synaptotagmin-12 is phosphorylated only on serine$^{97}$ either because another constitutively active protein kinase phosphorylates this amino acid or because, in these cultured neurons, PKA is activated.

To determine whether synaptotagmin-12 regulates evoked or spontaneous neurotransmitter release, we monitored inhibitory postsynaptic currents (IPSCs) in noninfected neurons or neurons expressing recombinant wild-type or S97A mutant synaptotagmin-12. We found that expression of wild-type synaptotagmin-12 increased the frequency of spontaneous release events threefold, but had no effect on their amplitude (Fig. 5, D–G). In contrast to spontaneous minis, synaptotagmin-12 had no effect on the sizes or kinetics of evoked responses, either when these were elicited by isolated single-action potentials or by high-frequency stimulus trains, indicating that both synchronous and asynchronous components or evoked release were unaffected (Fig. 6). Importantly, expression of S97A mutant synaptotagmin-12 had no effect on spontaneous release (Fig. 5, D and E), even though the mutant protein was expressed at the same level as wild-type synaptotagmin-12 (Fig. 5, A and B).

Several previous studies indicated that spontaneous release is up-regulated by cAMP-dependent pathways (Chavez-Noriega and Stevens, 1994; Capogna et al., 1995; Yoshihara et al., 2000; Doi et al., 2002). To test the possibility that the effect of synaptotagmin-12 on spontaneous release—which depends on the PKA-substrate site at serine$^{97}$—intersects with the PKA-dependent regulation of spontaneous release, we examined the effect of forskolin (an activator of adenylate cyclase) on spontaneous release. We found that in control cultures, forskolin caused an ~4.5-fold increase in the rate of spontaneous release.
release (Fig. 5, D and E), but had no effect on evoked release (Fig. S2, available at http://www.jcb.org/cgi/content/full/jcb.200607021/DC1). In cultures expressing wild-type synaptotagmin-12, the increase in mini frequency induced by forskolin was much more potent than in control cultures, whereas in cultures expressing S97A mutant synaptotagmin-12, the effect of forskolin was identical to that observed in control cultures (Fig. 5, D and E).

Synaptotagmin-12 binding to synaptotagmin-1

To obtain clues to the mechanism of action of synaptotagmin-12 in its selective effect on spontaneous release, we investigated whether synaptotagmin-12 might interact with SNARE proteins because binding to SNARE proteins is a salient property of other synaptotagmins (Bennett et al., 1992; Yoshida et al., 1992; Li et al., 1995; Chapman et al., 1995; Kee and Scheller, 1996; Banerjee et al., 1996; Rickman and Davletov, 2003; Rickman et al., 2004; Bowen et al., 2005; Tang et al., 2005). We performed immunoprecipitations of detergent-solubilized brain proteins with antibodies to synaptotagmin-1 and -12, and analyzed the immunoprecipitates for the presence of SNARE proteins and synaptotagmins. These experiments failed to reveal binding of synaptotagmin-12 to SNARE proteins, but showed that synaptotagmin-1 was coimmunoprecipitated with synaptotagmin-12 (Fig. 7 A), and that synaptotagmin-12 was coimmunoprecipitated with synaptotagmin-1 (Fig. 7 B). SNARE proteins were selectively absent from the synaptotagmin-12 immunoprecipitates, but were present in the synaptotagmin-1 immunoprecipitates. Equal amounts of synaptotagmin-1 and -12 were coimmunoprecipitated in the presence of either 1 mM free Ca$^{2+}$ or EGTA, suggesting that the interaction between these proteins is Ca$^{2+}$-independent (Fig. 7, A and B). Quantitations revealed that the equal amounts of synaptotagmin-1 and -12 were
coimmunoprecipitated from nontreated brain homogenates and homogenates preincubated with PKA activator 8-Br-cAMP (1 mM), PKA inhibitor H-89 (5 μM), or PKC activator PDBu (1 μM), suggesting that interaction between synaptotagmin-1 and -12 is not regulated by phosphorylation (Fig. 7, C–F).

**Synaptotagmin-12 regulates spontaneous release independent of synaptotagmin-1**

To determine whether synaptotagmin-12 regulates spontaneous release through interaction with synaptotagmin-1, we infected cortical neurons isolated from newborn synaptotagmin-1-deficient mice (Geppert et al., 1994) with lentiviruses expressing wild-type and S97A mutant synaptotagmin-12. We then monitored spontaneous release and release triggered by action potentials (Fig. 8).

Because deletion of synaptotagmin-1 results in an increase in the rate of spontaneous release (Maximov and Südhof, 2005; Pang et al., 2006), we measured spontaneous release in a lower concentration of extracellular Ca²⁺ that allows us to resolve individual miniature IPSC events. We found that similar to wild-type neurons, expression of synaptotagmin-12 in synaptotagmin-1-deficient neurons enhanced the rate of spontaneous release (Fig. 8, E and F), but did not alter evoked release triggered by action potentials (Fig. 8, A–D). Because evoked release is completely asynchronous in synaptotagmin-1-deficient neurons (Maximov and Südhof, 2005), synaptotagmin-12, thus, does not significantly alter asynchronous release. Although the increase in spontaneous release in synaptotagmin-1-deficient neurons expressing synaptotagmin-12 was not as dramatic as in wild-type cultures, the increase was still dependent on the phosphorylation of synaptotagmin-12 because the S97A mutant synaptotagmin-12 was unable to potentiate the mini IPSC (mIPSC) rate (Fig. 8, E and F). In these experiments, we could not determine the effects of forskolin on mIPSC frequency because the rate of spontaneous release was already too high.
Discussion

In this study, we demonstrate that synaptotagmin-12 is a synaptic vesicle protein that is widely expressed in the brain with a developmentally delayed onset (Fig. 1). Although synaptotagmin-12 is highly homologous to synaptotagmin-1 (which functions as the Ca$^{2+}$ sensor for fast synaptic vesicle exocytosis), and is colocalized with synaptotagmin-1 on synaptic vesicles (Fig. 2 and Fig. S1), synaptotagmin-12 differs from synaptotagmin-1 in that it does not bind Ca$^{2+}$ and phospholipids (Fig. 3 and not depicted). We also demonstrate that it is phosphorylated in a cAMP-dependent manner at a single residue, serine$^{97}$ (Fig. 4).

Because it is expressed in a developmentally delayed pattern, cultured neurons contain very low levels of endogenous synaptotagmin-12. Overexpression of recombinant synaptotagmin-12 in these neurons dramatically increased the rate of spontaneous release (Fig. 5), but had no effect on synchronous and asynchronous components of release triggered by action potentials (Fig. 6).

At least two alternative hypotheses could potentially explain how synaptotagmin-12 controls spontaneous neurotransmitter release: (1) synaptotagmin-12 regulates spontaneous release via its interaction with synaptotagmin-1, and (2) synaptotagmin-12 acts as an independent modulator of spontaneous release.

The first hypothesis is supported by the observation that synaptotagmin-12 forms a constitutive Ca$^{2+}$-independent heterooligomeric complex with synaptotagmin-1 that is incompatible with the interaction of synaptotagmin-1 with SNARE complexes (Fig. 7). Previous studies indicate that synaptotagmin-1 is associated with SNARE complexes in a Ca$^{2+}$-independent manner (Kee and Scheller, 1996; Rickman and Davletov, 2003), and that deletion of synaptotagmin-1 increases the rate of excitatory and inhibitory minis (Maximov and Südhof, 2005; Pang et al., 2006), suggesting that freeing SNARE complexes from synaptotagmin-1 may disinhibit spontaneous release. Our finding that synaptotagmin-12 interacts with synaptotagmin-1 suggests that synaptotagmin-12 increases spontaneous neurotransmitter release by pulling synaptotagmin-1 off SNARE complexes, and thereby disinhibiting spontaneous exocytosis. The alternative hypothesis would be that synaptotagmin-12 regulates spontaneous release by a synaptotagmin-1–independent (but phosphorylation-dependent) mechanism, and that the interaction of synaptotagmin-12 with synaptotagmin-1 performs an additional, as yet undetermined, role.

To test the two hypotheses, we determined the effect of overexpression of synaptotagmin-12 in synaptotagmin-1–deficient neurons (Fig. 8). We found that in the absence of synaptotagmin-1, synaptotagmin-12 still produced an increase, albeit a moderate one, in the rate of spontaneous exocytosis. This result favors the second hypothesis, suggesting that the phosphorylation site–dependent modulation of mini release by synaptotagmin-12 does not require synaptotagmin-1. It is also unlikely that the effect of expression of synaptotagmin-12 on spontaneous release is caused by a massive change in synapse density or in the size of the readily releasable pool of synaptic vesicles because we observed no differences between neurons expressing or lacking wild-type or mutant synaptotagmin-12 in evoked synaptic responses; this applies both for responses triggered by single-action potentials or by trains of action potentials (Figs. 6 and 8). A recent study has shown that spontaneous release is driven by an isolated pool of synaptic vesicles containing synaptotagmin-1 and controlled by synaptobrevin/VAMP2.
(Sara et al., 2005). It is conceivable that synaptotagmin-12 selectively regulates spontaneous release because it is only localized on this subpopulation of vesicles, but further biochemical analysis with an antibody against the luminal domain of synaptotagmin-12 will be required to test this possibility.

Our findings have several implications for the understanding of synaptic transmission. First, the possible biological role of spontaneous release events is widely debated, with opinions ranging from considering such events as mere accidental by-products of turbo-charged fusion machinery to biologically meaningful processes of synaptic communication (Otsu and Murphy, 2003; Zucker, 2005). Our data, by identifying a synaptic vesicle synaptotagmin isoform that selectively regulates spontaneous release in cultured neurons, lend credence to the notion that spontaneous release is a highly specific and regulated event. Notably, the rate of spontaneous release increases with age (Hsia et al., 1998), as do the expression levels of synaptotagmin-12. This finding suggests a connection, but several other factors such as developmental changes in connectivity and synapse maturation must also play a major role in this process (Hsia et al., 1998).

Although the effect of synaptotagmin-12 in cultured neurons is specific for spontaneous as opposed to evoked release, this does not exclude the possibility that in an intact brain, synaptotagmin-12 could participate in PKA-dependent forms of plasticity. It is noticeable that synaptotagmin-12 was discovered as a thyroid hormone–inducible gene (Thompson, 1996; Dong et al., 2005) and comes on relatively late in development, suggesting that its role is under further regulation beyond the phosphorylation by PKA. Moreover, extensive studies indicate that cAMP-dependent phosphorylation regulates exocytosis in non-neuronal cells (Koh et al., 2000) and neurons (Chavez-Noriega and Stevens, 1994; Capogna et al., 1995; Yoshihara et al., 2000; Doi et al., 2002). Multiple pathways have been implicated in the cAMP-dependent modulation of synaptic strength (Chavez-Noriega and Stevens, 1994; Capogna et al., 1995; Carroll et al., 1998; Sakaba and Neher, 2001; Kaneko and Takahashi, 2004). The requirement of serine57 for the effect of synaptotagmin-12 on spontaneous release indicates that synaptotagmin-12 may be generally involved in the regulation of synaptic vesicle exocytosis by PKA-dependent phosphorylation. Finally, expression of synaptotagmin-12 was detected in adrenal glands (Fig. 1 B), suggesting that synaptotagmin-12 may also be localized on dense core vesicles and play a role in regulating calcium-independent secretion in nonneuronal cells.

Materials and methods

Plasmid construction

The following vectors were constructed for expression of various regions of rat synaptotagmin-12 as GST fusion proteins: pGEX-KG-synaptotagmin-12-linker (aa 47–150); pGEXKG-synaptotagmin-12C-A (aa 151–281); and pGEXKG-synaptotagmin-12C-B (aa 282–421). For construction of synaptotagmin-12 lentivirus, full-length cDNA (aa 1–421) was subcloned into pFUGW shuttle vector. The point mutations were generated by PCR and verified by sequencing.

Antibody production

To generate a polyclonal antibody against synaptotagmin-12, the linker region of rat synaptotagmin-12 (aa 47–150) was expressed in BL-21 Escherichia coli strain as GST fusion protein and purified by affinity chromatography on glutathione–Agarose beads (GE Healthcare). The protein was eluted from the beads by 20 mM glutathione, dialyzed twice against PBS, and used for immunization at concentration of ~1 mg/ml. The specificity of the serum was confirmed by immunoblotting of full-length recombinant synaptotagmins 1–13 expressed in COS7 cells. The antibody was then purified by sequential affinity chromatography on the columns containing GST and GST-synaptotagmin-12 linker covalently attached to NHS-Sepharose beads (Pierce Chemical Co.).

Subcellular fractionation

Whole rat brains, including cerebellum and olfactory bulb, were homogenized in 0.32 M sucrose, 25 mM Hepes, pH 7.2, and centrifuged at 800 g to remove the nuclear fraction. The postnuclear supernatant (PNS) was centrifuged at 12,000 g to separate the soluble (synaptosomal supernatant) and membrane (synaptosomal pellet) fractions. The synaptosomal pellet was hypotonically lysed by incubation for 30 min in 5 mM Tris, pH 7.2, and recentrifuged at 27,000 g to separate the crude synaptic plasma membranes and crude synaptic vesicles. The crude synaptic plasma membrane fraction was adjusted to 1.1 M sucrose, loaded to the bottom of the centrifuge tube, and layered by solutions of 0.86 and 0.32 M sucrose. The samples were then centrifuged at 19,000 RPM (SW41 Ti rotor; Beckman Coulter) to separate synaptic plasma membranes, myelin, and mitochondria. All fractions were adjusted to the total protein concentration of 4 mg/ml and analyzed by immunoblotting. Approximately 40 μg of total protein was loaded into each lane (Fig. 3 C).

Immunoprecipitations

Rat brains were homogenized in 50 mM Hepes, 100 mM NaCl, 2 mM MgCl2, 4 mM EGTA, pH 6.8, and solubilized for 2 h at 4°C in the same buffer containing 1% Triton X-100. The samples were then centrifuged for 1 h at 50,000 RPM (70 Ti rotor; Beckman Coulter) to remove insoluble material and incubated for 2 h at 4°C with protein A–or protein G–Sepharose beads (GE Healthcare) covered with polyclonal antibody to synaptotagmin-12, monoclonal antibody to synaptotagmin-1, corresponding preimmune serum, or control antibody. The protein complexes attached to the beads were washed five times with the extraction buffer, eluted with SDS sample buffer, and analyzed by SDS PAGE and immunoblotting. The input lanes were loaded with 1% of total protein extract used for immunoprecipitation. To determine the effects of activators or inhibitors of PKA-dependent phosphorylation, the brain homogenates were preincubated for 30 min with 1 mM 8-Br-cAMP, 5 μM H-89, or 1 μM PDBu (used as a negative control) before protein extraction, and the immunoprecipitations were carried in the presence of EGTA, as described above.

Cortical and hippocampal primary neuronal cultures

The cortices or hippocampi were dissected from the brains of embryonic day 18 embryos or newborn pups, dissociated by trypsin digestion, and plated on circle glass coverslips coated with Matrigel. The cultures were maintained in MEM medium (Invitrogen) supplemented with B-27 (Invitrogen), 2 mM glutamine, 0.5% glucose, 5% fetal bovine serum, and 2 mM Ara-C (Sigma-Aldrich). The cultures were used for experiments at 14–17 DIV.

Immunocytochemistry

Neurons attached to the glass coverslips were rinsed once in PBS, fixed for 15 min on ice in 4% formaldehyde, 4% sucrose in PBS and permeabilized for 5 min at room temperature in 0.2% Triton X-100 (Roche) in PBS. After permeabilization, the neurons were incubated for 30 min in blocking solution containing 5% BSA (Sigma-Aldrich; fraction V) in PBS, followed by 1-h incubation with primary and rhodamine- and FITC-conjugated secondary antibodies diluted in blocking solution. The coverslips were then mounted on slides with Aquamount medium (Polysciences, Inc.) and analyzed at room temperature using a confocal microscope (DMIRE2; Leica) and 63×/1.32–0.6 oil immersion objective. The images were collected using confocal software (Leica) and processed using Photoshop software (Adobe). The background fluorescence was digitally reduced by 25% using the “color balance” function in Photoshop. All digital manipulations were equally applied to the entire image. Brain sections from perfusion-fixed rats were permeabilized for 10 min in 0.5% Triton X-100 in PBS and incubated in blocking buffer containing 2% goat serum and 0.1% Triton X-100 in PBS. The sections were then incubated sequentially for 1 h in primary and secondary antibodies diluted in blocking buffer and developed in DAB substrate. For dehydration, the sections were incubated for 10 min in 70% ethanol, followed by 10-min incubation in 90% ethanol and 10-min incubation in 100% ethanol. The sections were then mounted on glass slides and analyzed by light microscopy.
Immunelectron microscopy

Adult mouse brains were perfusion fixed in 4% paraformaldehyde and 0.1% glutaraldehyde in PBS, pH 7.4, followed by overnight immersion fixation in 0.1% glutaraldehyde and 2% paraformaldehyde. The brain sections (120 μm) were permeabilized in 0.2% Triton X-100, blocked in 4% normal goat serum, and incubated overnight with primary antibody alone or primary antibody mixed with the antigen (~1 mg/ml). The sections were then incubated with the secondary antibody conjugated with 1.4-nm gold particles (1:100 dilution; Nanoprobe) for 24 h, and immunogold signal was enhanced with the HQ silver enhancement kit (Nanoprobe). Sections were further fixed with 0.5% osmium tetroxide, dehydrated through a graded series of ethanol, and embedded in Poly/Bed 812 epoxy resin (Polysciences, Inc.). Ultrathin sections (65 nm) were stained with 5% uranyl acetate solution and examined under a transmission electron microscope (FEI Tecnai; FEI) at 120 kV accelerating voltage.

Phosphorylation

Synaptosomes (~1 mg of total protein) were prelabeled for 30 min at 37°C in phosphate-free aerated Krebs-Henseleit-Hepes buffer (118 mM NaCl, 3.5 mM KCl, 1.25 mM CaCl2, 1.2 mM MgSO4, 25 mM NaHCO3, 5 mM Hepes-NaOH, pH 7.4, and 115 mM glucose) containing 0.3 mM cAMP, 0.1 mM cGMP, or 1 mM Ca2+ through a local extracellular electrode (FHC, Inc.) and recorded in a whole-cell mode by neurons expressing recombinant protein of interest. Inhibitory synapses (as determined by GFP fluorescence and immunocytochemistry with anti-GFP antibody) were dried and exposed to x-ray film for 24–48 h at −80°C. The currents were sampled at 10 kHz and analyzed off-line using pClamp9 (Axon Instruments, Inc.) and Origin7 (Microcal, Inc.) software. mIPSCs event detection was performed with pClamp template search function using a template constructed by averaging ~100 manually collected individual mIPSCs. Statistical analysis was performed with T-test; ***, * P < 0.001. All data are shown as the mean ± SEM.

Miscellaneous

Production of recombinant lentiviruses, phospholipid-binding assays, deglycosylation, and immunoblotting were performed as previously described [Shin et al., 2003; Han et al., 2004; Maximov and Südhof, 2005].

Online supplemental material

Fig. S1 shows localization of synaptotagmin-12 in brain slices. Fig. S2 shows the effect of Forskolin on evoked release in inhibitory synapses of cultured cortical neurons. Online supplemental material is available at http://www.jcb.org/cgi/content/full/jcb.200607021/DC1.

We would like to thank I. Kombilm and A. Roth for their expert technical assistance.

Submitted: 6 July 2006
Accepted: 29 November 2006

References


http://www.jcb.org/cgi/content/full/jcb.200607021/DC1
Thompson, C.C. 1996. Thyroid hormone-responsive genes in developing cerebellum include a novel synaptotagmin and a hairless homolog. J. Neurosci. 16:7832–7840.